| Expression pattern: |
DN |
| Associated gene: |
LEFTY2 |
| Associated microRNA: |
hsa-miR-1291 |
| Biological function: |
inhibits HSC activation and proliferation; alleviates hepatic fibrosis injury; reduces collagen deposition |
| Molecular mechanism: |
ceRNA mechanism: circCREBBP sponges hsa-miR-1291 to promote LEFTY2 expression |
| Biological pathway or process: |
ceRNA regulation (promotes); proliferation (inhibits); cell cycle (inhibits); fibrosis (inhibits) |
| Detected method: |
Q
S
|
| Validation methods: |
circRNA-seq; RT-qPCR; divergent primers PCR; Sanger Sequencing; FISH / smFISH; Microarray; Bioinformatics Analysis; Luciferase Reporter Assay; Transfection; CCK8; Cell Cycle Assay; Western Blot; In Vivo Animal Model; H&E Staining; IHC (Immunohistochemistry) |
| Clinical significance: |
potential value as a diagnostic and prognostic indicator of HF; may be a promising biomarker for the treatment of HF |
| Description: |
circCREBBP is down-regulated in hepatic fibrosis and exerts anti-fibrotic effects by inhibiting hepatic stellate cell activation and proliferation. Mechanistically, it functions as a ceRNA by sponging hsa-miR-1291 to increase LEFTY2 expression, thereby alleviating fibrosis in vitro and in a CCl4-induced mouse model. |
| Confidence score: |
0.8067 |